Western Standard LLC’s 2seventy bio TSVT Stock Holding History

Western Standard LLC’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-788,350	Closed	-$2.32M	–	32
2024 Q4	$2.32M	Buy	788,350 +502,419	+176%	+$2.06M	1.54%	22
2024 Q3	$1.35M	Buy	+285,931	New	+$1.29M	1.27%	21

Other funds holding TSVT

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Western Standard LLC's TSVT Position: Q1 2025 in Review

Western Standard LLC sold out of 2seventy bio (TSVT) in Q1 2025, closing a stake of 788,350 shares — an estimated $2.32M sold.

Western Standard LLC first reported a position in TSVT in Q3 2024 and held it in 2 quarters. The position peaked at $2.32M in Q4 2024. 139 funds tracked by Wall St. Rank hold TSVT as of Q1 2025.

Western Standard LLC reported no remaining 2seventy bio position as of Q1 2025 after selling out during the quarter.
Western Standard LLC sold 788,350 2seventy bio shares in Q1 2025, an estimated $2.32M.
Western Standard LLC first reported a position in 2seventy bio in Q3 2024 and held it in 2 quarters.
Western Standard LLC's 2seventy bio position peaked at $2.32M in Q4 2024.
139 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2025.

Based on Western Standard LLC's 13F filing for Q1 2025, filed 15 May 2025.